(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.67%) $83.29
(-1.16%) $1.619
(-0.02%) $2 346.80
(-0.04%) $27.53
(0.21%) $924.00
(-0.09%) $0.934
(-0.01%) $11.02
(-0.12%) $0.799
(0.00%) $92.17
1.83% € 94.60
Live Chart Being Loaded With Signals
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases...
Stats | |
---|---|
Volumen de hoy | 49 622.00 |
Volumen promedio | 20 205.00 |
Capitalización de mercado | 4.21B |
EPS | €0 ( 2024-03-14 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 47.78 |
ATR14 | €0.139 (0.15%) |
Volumen Correlación
Financiere de Tubize SA Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Financiere de Tubize SA Correlación - Moneda/Commodity
Financiere de Tubize SA Finanzas
Annual | 2023 |
Ingresos: | €0 |
Beneficio Bruto: | €-2.03M (0.00 %) |
EPS: | €1.980 |
FY | 2023 |
Ingresos: | €0 |
Beneficio Bruto: | €-2.03M (0.00 %) |
EPS: | €1.980 |
FY | 2022 |
Ingresos: | €8 151.00 |
Beneficio Bruto: | €-1.82M (-22 327.55 %) |
EPS: | €3.91 |
FY | 2021 |
Ingresos: | €0.00 |
Beneficio Bruto: | €0.00 (0.00 %) |
EPS: | €8.54 |
Financial Reports:
No articles found.
Financiere de Tubize SA
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico